Ceritinib (LDK378, LDK-378)，又称色瑞替尼，是可口服、ATP竞争性的ALK酪氨酸激酶选择性抑制剂，IC₅₀为200 pM，临床上用于ALK阳性转移性非小细胞肺癌治疗，对表达EML4-ALK、NPM-ALK融合蛋白的癌细胞有抑制作用。

参考文献

1. Marsilje TH, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013 Jul 25;56(14):5675-90.
2. Chen J, et al. LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. J Med Chem. 2013 Jul 25;56(14):5673-4.
3. Tucker ER, et al. Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma. Mol Oncol. 2017 Aug;11(8):996-1006.

冰袋运输。粉末直接保存于-25~-15℃，有效期3年。建议分装后-25~-15℃干燥保存，避免反复冻融。